Related references
Note: Only part of the references are listed.Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
X. H. Wu et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Ovarian Cancer, Version 2.2020
Deborah K. Armstrong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
Yangchun Xu et al.
FRONTIERS IN ONCOLOGY (2021)
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020
Wei Cao et al.
CHINESE MEDICAL JOURNAL (2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andres Poveda et al.
LANCET ONCOLOGY (2021)
Fuzuloparib: First Approval
Arnold Lee
DRUGS (2021)
Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer
Binghe Xu et al.
CANCER MEDICINE (2021)
Comparison of four heterogeneity measures for meta-analysis
Lifeng Lin
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2020)
Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials
Fengping Shao et al.
BIOSCIENCE REPORTS (2020)
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Wenhua Liang et al.
LANCET ONCOLOGY (2020)
The kinase polypharmacology landscape of clinical PARP inhibitors
Albert A. Antolin et al.
SCIENTIFIC REPORTS (2020)
Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis
Ezzeldin M. Ibrahim et al.
FUTURE ONCOLOGY (2020)
Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis
Peiwei Chai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
Jing Yu et al.
JAMA ONCOLOGY (2020)
Cochrane Handbook for Systematic Reviews of Interventions
Mona Nasser
AMERICAN JOURNAL OF PUBLIC HEALTH (2020)
PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
Chiho Kim et al.
ELIFE (2020)
Gynecologic oncology at the time of COVID-19 outbreak
Giorgio Bogani et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2020)
The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression
Zhilan Zhang et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Stephanie Lheureux et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status
Federica Tomao et al.
CANCER TREATMENT REVIEWS (2019)
Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
Shuai Wang et al.
NATURE CHEMICAL BIOLOGY (2019)
Exploring and comparing adverse events between PARP inhibitors
Christopher J. LaFargue et al.
LANCET ONCOLOGY (2019)
Safety and dose modification for patients receiving niraparib
J. S. Berek et al.
ANNALS OF ONCOLOGY (2018)
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Ann-Gerd Thorsell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
A Cell-Line-Specific Atlas of PARP-Mediated Protein Asp/Glu-ADP-Ribosylation in Breast Cancer
Yuanli Zhen et al.
CELL REPORTS (2017)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A. Ledermann et al.
LANCET ONCOLOGY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation
Bryan A. Gibson et al.
SCIENCE (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
Jose Antonio Lopez-Guerrero et al.
CHINESE JOURNAL OF CANCER (2015)
Comparative Efficacy and Tolerability of Three Treatments in Old People with Osteoporotic Vertebral Compression Fracture: A Network Meta-Analysis and Systematic Review
Ling-Xiao Chen et al.
PLOS ONE (2015)
Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors
Albert A. Antolin et al.
ONCOTARGET (2014)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Interpretation of random effects meta-analyses
Richard D. Riley et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Improved Overall Survival with 12 Cycles of Single-Agent Paclitaxel Maintenance Therapy following a Complete Response to Induction Chemotherapy in Advanced Ovarian Carcinoma
Lisa N. Abaid et al.
ONCOLOGY (2010)
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2009)
Endpoints for assessing drug activity in clinical trials
Richard Pazdur
ONCOLOGIST (2008)
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Misleading meta-analysis
J Critchley et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2003)
Are increasing 5-year survival rates evidence of success against cancer?
HG Welch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
